Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
HGSOC
Vigil
ovarian cancer maintenance
ovarian cancer treatment
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
06
2020
accepted:
17
10
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
epublish
Résumé
While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose polymerase (PARP) inhibitors have recently gained approval in ovarian cancer maintenance. Niraparib was approved regardless of
Identifiants
pubmed: 33391401
doi: 10.7150/jca.49406
pii: jcav12p0038
pmc: PMC7738841
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
38-53Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Int J Mol Sci. 2020 Apr 28;21(9):
pubmed: 32354198
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
J Clin Oncol. 2003 Nov 15;21(22):4222-7
pubmed: 14615451
J Clin Oncol. 2013 Apr 20;31(12):1554-61
pubmed: 23478059
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Gynecol Oncol. 2011 Dec;123(3):456-60
pubmed: 21855120
BMC Cancer. 2017 Sep 20;17(1):657
pubmed: 28931370
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518089
J Clin Oncol. 2009 Nov 20;27(33):5601-6
pubmed: 19826113
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32369446
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077
pubmed: 33409454
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
JAMA. 2006 Jul 12;296(2):185-92
pubmed: 16835424
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Gynecol Oncol. 2014 May;133(2):362-9
pubmed: 24607283
MOJ Immunol. 2018;6(2):34-42
pubmed: 30637330
Onco Targets Ther. 2019 Sep 30;12:8015-8022
pubmed: 31686857
Cancers (Basel). 2019 Apr 18;11(4):
pubmed: 31003488
J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186
pubmed: 28338569
Gynecol Oncol. 2018 Nov;151(2):190-195
pubmed: 30268525
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
J Virol. 2014 May;88(10):5328-41
pubmed: 24600004
Crit Rev Immunol. 2013;33(2):137-64
pubmed: 23582060
Cells. 2020 Mar 14;9(3):
pubmed: 32183385
Gynecol Oncol. 2016 Jun;141(3):413-415
pubmed: 27138456
Expert Rev Anticancer Ther. 2018 Feb;18(2):177-186
pubmed: 29241375
J Biol Chem. 2016 Nov 25;291(48):25154-25166
pubmed: 27733682
Am J Obstet Gynecol. 2015 Apr;212(4):479.e1-479.e10
pubmed: 25446664
Mutat Res Rev Mutat Res. 2019 Apr - Jun;780:82-91
pubmed: 31395352
Br J Pharmacol. 2013 Oct;170(4):712-29
pubmed: 23962094
Gynecol Oncol Rep. 2019 Aug 13;29:102-105
pubmed: 31467961
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Clin Cancer Res. 2017 Jul 1;23(13):3453-3460
pubmed: 27986748
Cancer Treat Rev. 2019 Feb;73:1-9
pubmed: 30543930
Cancer Res. 2005 Dec 15;65(24):11597-604
pubmed: 16357170
Stem Cell Res Ther. 2015 Dec 30;6:262
pubmed: 26718286
Curr Top Microbiol Immunol. 2011;350:17-37
pubmed: 21061197
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Gynecol Oncol. 2010 Jun;117(3):497-504
pubmed: 20363017
Gene Ther. 2005 Mar;12(5):386-7
pubmed: 19202637
Ann Oncol. 2016 Jun;27(6):1013-1019
pubmed: 26961146
Cancer Res. 2010 Feb 1;70(3):875-82
pubmed: 20103634
Br J Cancer. 2007 Jan 15;96(1):11-5
pubmed: 17213823
Clin Cancer Res. 2004 Mar 1;10(5):1580-7
pubmed: 15014007
Cochrane Database Syst Rev. 2013 Jun 29;(6):CD007414
pubmed: 23813336
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Immunology. 2007 Nov;122(3):418-29
pubmed: 17617155
Gynecol Oncol. 2008 Aug;110(2):246-50
pubmed: 18495226
Lancet Oncol. 2019 Jan;20(1):e15-e28
pubmed: 30614472
Int J Oncol. 2016 Apr;48(4):1369-78
pubmed: 26892612
Onco Targets Ther. 2018 Jan 23;11:521-528
pubmed: 29416352
Br J Cancer. 2018 Nov;119(11):1401-1409
pubmed: 30353044
Cell Metab. 2016 Nov 8;24(5):728-739
pubmed: 27746051
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
J Clin Oncol. 2017 Jul 10;35(20):2240-2250
pubmed: 28448241
J Clin Oncol. 2017 Apr 1;35(10):1086-1095
pubmed: 28135145
Gynecol Oncol. 2016 Feb;140(2):204-9
pubmed: 26616225
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Ther Adv Med Oncol. 2018 Jun 22;10:1758835918778483
pubmed: 29977351
Oncoimmunology. 2018 Nov 16;8(2):e1535730
pubmed: 30713791
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Ther Adv Med Oncol. 2019 May 22;11:1758835919849753
pubmed: 31205507
Clin Med Insights Oncol. 2019 May 28;13:1179554919852071
pubmed: 31191068
Future Oncol. 2020 Apr;16(10):585-596
pubmed: 32166978
Microvasc Res. 2007 Sep-Nov;74(2-3):72-84
pubmed: 17560615
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
J Clin Oncol. 2009 Jan 20;27(3):418-25
pubmed: 19075271
Mol Ther. 2012 Mar;20(3):679-86
pubmed: 22186789
J Immunol Res. 2015;2015:761820
pubmed: 26568964
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106
pubmed: 28264872
Cell Stem Cell. 2017 Mar 2;20(3):303-314.e5
pubmed: 28041894
Gynecol Oncol. 2016 Dec;143(3):504-510
pubmed: 27678295
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Lancet. 2010 Oct 2;376(9747):1155-63
pubmed: 20888993
Genes Cancer. 2018 May;9(5-6):155-175
pubmed: 30603053
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
EMBO Rep. 2018 Dec;19(12):
pubmed: 30446584
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Nat Rev Cancer. 2005 Sep;5(9):689-98
pubmed: 16110319
N Engl J Med. 2008 May 8;358(19):2039-49
pubmed: 18463380
J Clin Oncol. 2020 Apr 10;38(11):1164-1174
pubmed: 32073956
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s
pubmed: 30133561
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
J Clin Oncol. 2020 Oct 20;38(30):3468-3493
pubmed: 32790492
J Clin Oncol. 2002 Mar 15;20(6):1562-9
pubmed: 11896105
Int J Gynecol Cancer. 2018 Jun;28(5):903-914
pubmed: 29561301
Nat Rev Cancer. 2011 Dec 23;12(1):68-78
pubmed: 22193408
Clin Cancer Res. 2020 Nov 1;26(21):5631-5637
pubmed: 32723836
Cancer Res. 2010 Oct 15;70(20):8045-54
pubmed: 20924112
Br J Cancer. 2019 Feb;120(4):424-434
pubmed: 30718808
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Adv Cancer Res. 2015;128:263-307
pubmed: 26216636
BJOG. 2021 Feb;128(3):485-493
pubmed: 32654312
Oncoimmunology. 2012 Dec 1;1(9):1577-1583
pubmed: 23264903
Br J Cancer. 2012 Jan 31;106(3):468-74
pubmed: 22223088
Gynecol Oncol. 2015 Jul;138(1):55-61
pubmed: 25895616
N Engl J Med. 1999 Feb 4;340(5):351-7
pubmed: 9929525
Sci Rep. 2016 May 18;6:26191
pubmed: 27189670
CA Cancer J Clin. 2011 May-Jun;61(3):183-203
pubmed: 21521830
Clin Cancer Res. 2010 Jul 15;16(14):3594-606
pubmed: 20628030
J Clin Oncol. 2007 Jul 10;25(20):2902-8
pubmed: 17617521
J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72
pubmed: 12237282
Oncologist. 2010;15(8):819-25
pubmed: 20688807
Mol Oncol. 2009 Apr;3(2):138-50
pubmed: 19383375
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Mol Ther. 2015 Jun;23(6):1103-1109
pubmed: 25917459
Br J Cancer. 2017 Mar 28;116(7):884-892
pubmed: 28222073
J Transl Med. 2015 Mar 28;13:102
pubmed: 25890361
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Drug Des Devel Ther. 2017 Oct 13;11:3009-3017
pubmed: 29075104
J Clin Oncol. 2004 Sep 1;22(17):3507-16
pubmed: 15337799
Gynecol Oncol. 2004 Aug;94(2):340-51
pubmed: 15297171
Mol Ther. 2016 Aug;24(8):1478-83
pubmed: 27109631
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683